|
Molecular properties generated using the CDK |
Classification ![]() |
|
Compound class | Synthetic organic |
IUPAC Name ![]() |
N-(2-diethylaminoethyl)-2-[2-[(4-fluorophenyl)methylsulfanyl]-4-oxo-6,7-dihydro-5H-cyclopenta[e]pyrimidin-1-yl]-N-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide |
International Nonproprietary Names ![]() |
|
INN number | INN |
8703 | darapladib |
Synonyms ![]() |
SB 480848 | SB-480848 |
Comments |
Darapladib is a potent PLA2G7 (commonly referred to as Lp-PLA2) inhibitor. Darapladib and analogues such as rilapladib are clinical drug candidates with potential to reduce the risk of atherosclerosis and associated clinical sequelae [10]. |
Database Links ![]() |
|
CAS Registry No. | 356057-34-6 (source: PubChem) |
ChEMBL Ligand | CHEMBL204021 |
GtoPdb PubChem SID | 178103307 |
PubChem CID | 9939609 |
RCSB PDB Ligand | 5HV |
Search Google for chemical match using the InChIKey | WDPFJWLDPVQCAJ-UHFFFAOYSA-N |
Search Google for chemicals with the same backbone | WDPFJWLDPVQCAJ |
Search PubMed clinical trials | darapladib |
Search PubMed titles | darapladib |
Search PubMed titles/abstracts | darapladib |
Search UniChem for chemical match using the InChIKey | WDPFJWLDPVQCAJ-UHFFFAOYSA-N |
Search UniChem for chemicals with the same backbone | WDPFJWLDPVQCAJ |
SynPHARM |
78680 (in complex with PLA2-G7) 84827 (in complex with PLA2-G7) 84828 (in complex with PLA2-G7) |
Wikipedia | Darapladib |